Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

Get Started

Home
Investing
Stocks
UK
LSE
Bergenbio Asa (0RU5)
Bergenbio Asa (0RU5) News

0RU5

Bergenbio Asa (0RU5)

Bergenbio Asa

Date:

Regulatory News

Text Search:

Sort by:

Non-Regulatory News

Showing the most relevant articles for your search:LSE:0RU5

1 2 3 4 5 6 7 Next >>

Date	Time	Source	Headline	Symbol	Company
08/22/2023	4:50AM	PR Newswire (US)	BerGenBio announces clinical data presentations highlighting the activity of its selective AXL inhibitor bemcentinib in Non-Small Cell Lung Cancer	LSE:0RU5	Bergenbio Asa
08/22/2023	4:45AM	PR Newswire (US)	BerGenBio announces clinical data presentations highlighting the activity of its selective AXL inhibitor bemcentinib in Non-Small Cell Lung Cancer	LSE:0RU5	Bergenbio Asa
05/26/2023	9:07AM	PR Newswire (US)	BerGenBio ASA: Approval and publication of prospectus for the preferential Rights Issue	LSE:0RU5	Bergenbio Asa
04/25/2023	12:26PM	PR Newswire (US)	BerGenBio ASA: Proposed partially underwritten rights issue	LSE:0RU5	Bergenbio Asa
04/18/2023	1:23AM	PR Newswire (US)	BerGenBio Presents Data on STK11 Loss of Function and AXL Activation at AACR	LSE:0RU5	Bergenbio Asa
04/18/2023	1:20AM	PR Newswire (US)	BerGenBio Presents Data on STK11 Loss of Function and AXL Activation at AACR	LSE:0RU5	Bergenbio Asa
03/09/2023	5:22AM	PR Newswire (US)	BerGenBio Announces First Patient Dosed in Phase 1b/2a Trial Evaluating Bemcentinib in 1st Line Non-Small Cell Lung Cancer with STK11 Mutations	LSE:0RU5	Bergenbio Asa
03/09/2023	5:20AM	PR Newswire (US)	BerGenBio Announces First Patient Dosed in Phase 1b/2a Trial Evaluating Bemcentinib in 1st Line Non-Small Cell Lung Cancer with STK11 Mutations	LSE:0RU5	Bergenbio Asa
02/16/2023	1:32AM	PR Newswire (US)	BerGenBio Reports Fourth Quarter 2022 Financial Results and Provides Business Update	LSE:0RU5	Bergenbio Asa
02/16/2023	1:30AM	PR Newswire (US)	BerGenBio Reports Fourth Quarter 2022 Financial Results and Provides Business Update	LSE:0RU5	Bergenbio Asa
02/15/2023	11:35AM	PR Newswire (US)	BerGenBio Announces Positive Data From Phase 2 Trial of Bemcentinib in Combination with Pembrolizumab in 2L+ NSCLC Patients	LSE:0RU5	Bergenbio Asa
02/15/2023	11:31AM	PR Newswire (US)	BerGenBio Announces Positive Data From Phase 2 Trial of Bemcentinib in Combination with Pembrolizumab in 2L+ NSCLC Patients	LSE:0RU5	Bergenbio Asa
02/02/2023	1:17AM	PR Newswire (US)	BerGenBio Announces the Establishment of Oncology Scientific Advisory Board	LSE:0RU5	Bergenbio Asa
02/02/2023	1:15AM	PR Newswire (US)	BerGenBio Announces the Establishment of Oncology Scientific Advisory Board	LSE:0RU5	Bergenbio Asa
11/15/2022	1:10AM	PR Newswire (US)	BerGenBio reports third quarter 2022 financial results and provides business update	LSE:0RU5	Bergenbio Asa
11/15/2022	1:07AM	PR Newswire (US)	BerGenBio reports third quarter 2022 financial results and provides business update	LSE:0RU5	Bergenbio Asa
10/25/2022	1:37AM	PR Newswire (US)	BerGenBio ASA Secures NOK 100 million Shareholder Loan Facility from Meteva AS	LSE:0RU5	Bergenbio Asa
10/25/2022	1:34AM	PR Newswire (US)	BerGenBio ASA Secures NOK 100 million Shareholder Loan Facility from Meteva AS	LSE:0RU5	Bergenbio Asa
10/11/2022	1:36AM	PR Newswire (US)	BerGenBio Announces Initiation of Phase 1b/2a Trial Evaluating Bemcentinib in 1st line Non-Small Cell Lung Cancer Patients Harboring STK11 Mutations	LSE:0RU5	Bergenbio Asa
10/11/2022	1:34AM	PR Newswire (US)	BerGenBio Announces Initiation of Phase 1b/2a Trial Evaluating Bemcentinib in 1st line Non-Small Cell Lung Cancer Patients Harboring STK11 Mutations	LSE:0RU5	Bergenbio Asa
09/27/2022	9:31AM	PR Newswire (US)	BERGENBIO ANNOUCES FIRST PATIENT RANDOMIZED IN BEMCENTINIB TRIAL IN EU-SOLIDACT PLATFORM FOR HOSPITALIZED COVID-19 PATIENTS	LSE:0RU5	Bergenbio Asa
09/27/2022	9:28AM	PR Newswire (US)	BERGENBIO ANNOUCES FIRST PATIENT RANDOMIZED IN BEMCENTINIB TRIAL IN EU-SOLIDACT PLATFORM FOR HOSPITALIZED COVID-19 PATIENTS	LSE:0RU5	Bergenbio Asa
08/23/2022	1:36AM	PR Newswire (US)	BerGenBio reports second quarter and half year 2022 financial results and provides business update	LSE:0RU5	Bergenbio Asa
08/23/2022	1:34AM	PR Newswire (US)	BerGenBio reports second quarter and half year 2022 financial results and provides business update	LSE:0RU5	Bergenbio Asa
05/04/2022	1:29AM	PR Newswire (US)	BERGENBIO ANNOUNCES LAUNCH OF BUSINESS STRATEGY FOCUSED ON NSCLC AND COVID-19	LSE:0RU5	Bergenbio Asa
05/04/2022	1:27AM	PR Newswire (US)	BERGENBIO ANNOUNCES LAUNCH OF BUSINESS STRATEGY FOCUSED ON NSCLC AND COVID-19	LSE:0RU5	Bergenbio Asa
04/26/2022	1:13AM	PR Newswire (US)	BERGENBIO ANNOUNCES COMPLETE DATA ANALYSIS OF ACCORD2 PHASE II BEMCENTINIB STUDY IN HOSPITALIZED COVID-19 PATIENTS - PRIMARY EFFICACY ENDPOINT MET	LSE:0RU5	Bergenbio Asa
04/26/2022	1:12AM	PR Newswire (US)	BERGENBIO ANNOUNCES COMPLETE DATA ANALYSIS OF ACCORD2 PHASE II BEMCENTINIB STUDY IN HOSPITALIZED COVID-19 PATIENTS - PRIMARY EFFICACY ENDPOINT MET	LSE:0RU5	Bergenbio Asa
04/11/2022	1:12AM	PR Newswire (US)	BerGenBio strengthens its leadership team with appointment of Cristina Oliva as Chief Medical Officer	LSE:0RU5	Bergenbio Asa
04/07/2022	8:20AM	PR Newswire (US)	BERGENBIO ASA: BOARD APPROVAL OF 2021 ANNUAL FINANCIAL STATEMENT AND ANNUAL REPORT 2021	LSE:0RU5	Bergenbio Asa

Showing the most relevant articles for your search:LSE:0RU5

1 2 3 4 5 6 7 Next >>

International Endeavors (PK)

AMC Entertainment

Kraig Biocraft Laborator... (QB)

Ecare Solutions (PK)

Asia Broadband (PK)

North Bay Resources (PK)

Cann American (CE)

Voip Pal Com (QB)

Bioelectronics (PK)

Lightwave Logic

NaturalShrimp (QB)

Delayed Upgrade Clock

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions